WRF
TEVA icon

Waddell & Reed Financial’s Teva Pharmaceuticals TEVA Stock Holding History

Waddell & Reed Financial’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,930,671
Closed -$34M – 557
2017
Q3 		$34M Sell
1,930,671
-4,050,214
-68% -$91.1M 0.08% 278
2017
Q2 		$199M Sell
5,980,885
-2,099,000
-26% -$65M 0.44% 62
2017
Q1 		$259M Sell
8,079,885
-2,550,568
-24% -$87M 0.55% 49
2016
Q4 		$385M Sell
10,630,453
-6,639,455
-38% -$265M 0.84% 23
2016
Q3 		$795M Sell
17,269,908
-2,088,560
-11% -$109M 1.64% 4
2016
Q2 		$972M Buy
19,358,468
+896,033
+5% +$47.7M 2.05% 2
2016
Q1 		$988M Buy
18,462,435
+310,657
+2% +$18.2M 1.85% 3
2015
Q4 		$1.19B Buy
18,151,778
+2,304,912
+15% +$142M 1.93% 5
2015
Q3 		$895M Sell
15,846,866
-1,468,823
-8% -$95.2M 1.47% 10
2015
Q2 		$1.02B Buy
17,315,689
+74,107
+0.4% +$4.57M 1.46% 7
2015
Q1 		$1.07B Buy
17,241,582
+1,363,498
+9% +$79.3M 1.49% 10
2014
Q4 		$913M Buy
15,878,084
+1,203,796
+8% +$67.1M 1.27% 12
2014
Q3 		$789M Buy
14,674,288
+7,104,317
+94% +$376M 1.09% 19
2014
Q2 		$397M Buy
7,569,971
+1,528,869
+25% +$78.1M 0.58% 58
2014
Q1 		$319M Sell
6,041,102
-109,968
-2% -$5.08M 0.48% 65
2013
Q4 		$247M Buy
6,151,070
+1,531,330
+33% +$60.3M 0.4% 75
2013
Q3 		$175M Sell
4,619,740
-8,800
-0.2% -$343K 0.33% 84
2013
Q2 		$181M Buy
+4,628,540
New +$180M 0.38% 72

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Waddell & Reed Financial's TEVA Position: Q4 2017 in Review

Waddell & Reed Financial sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 1,930,671 shares — an estimated $34M sold.

Waddell & Reed Financial first reported a position in TEVA in Q2 2013 and held it in 18 quarters. The position peaked at $1.19B in Q4 2015. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Waddell & Reed Financial reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Waddell & Reed Financial sold 1,930,671 Teva Pharmaceuticals shares in Q4 2017, an estimated $34M.
  • Waddell & Reed Financial first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • Waddell & Reed Financial's Teva Pharmaceuticals position peaked at $1.19B in Q4 2015.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Waddell & Reed Financial's 13F filing for Q4 2017, filed 14 Feb 2018.